Outlook Therapeutics Reports Financial Results for Third Qua

14.08.2023 - Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) ISELIN, N.J., Aug. 14, 2023 (GLOBE ...

Related Keywords

United States , Japan , Ukraine , United Kingdom , China , Russia , Harriet Ullman , Jenene Thomas , Committee For Medicinal Products Human Use , Amerisourcebergen , Alliance Healthcare , Lavoie Health Science , Fujifilm , Exchange Commission , Outlook Therapeutics Inc , Aji Bio Pharma Services , Upcoming Anticipated , Planning Underway , Support Potential Approval , First Ophthalmic Formulation , Outlook Therapeutics , Pre Launch Preparations Proceeding , Marketing Authorization Application , Medicinal Products , Human Use , Syntone Biopharma , Special Protocol Assessments , Fiscal Third Quarter Ended June , Outlook Therapeutic , Annual Report ,